Clinical Trials | April 22, 2026
Ultomiris shows strong interim results in Phase III IgA nephropathy trial
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The company says the platform offers improved manufacturability and functional advantages
Subscribe To Our Newsletter & Stay Updated
